Most hospitals have no idea how much orphan drug revenue they are missing each quarter. A 340B Orphan Drug Savings Estimator built on real facility data changes that. 340B Orphan Drug Solutions offers exactly this kind of assessment, led by Dr. Lisa Nezneski, PharmD, BCPS, who has spent over 11 years focused exclusively on this niche.
What the estimate reveals:
- Which orphan drugs your facility currently purchases at full price
- Manufacturers currently offering discretionary 340B pricing
- Estimated dollars left uncaptured under current workflows
- How split-billing software could be configured to close the gap
- Quarterly pricing changes that affect your specific drug list
This is not a generic industry average. It is a facility-specific look at where savings are being missed under the 2013 HRSA orphan drug exclusion rule.
Request your 340B Orphan Drug Savings Estimator at https://340borphandrugsolutions.com/ and get direct access to a specialist, not a call center or chatbot.